Pretreatment platelet count early predicts extrahepatic metastasis of human hepatoma
Authors:
- 10 April 2015
- journal article
- research article
- Published by Wiley in Liver International
- Vol. 35 (10) , 2327-2336
Abstract
Background & Aims: Thrombocytosis is associated with metastasis in many human cancers. Most hepatocellular carcinomas (HCC) develop in cirrhotic livers, which are characterized by thrombocytopenia. We aimed to elucidate the pretreatment platelet count in prediction of extrahepatic metastasis of HCC during the follow‐up.Methods: Three cohorts containing 1660, 480 and 965 HCC patients enrolled from three hospitals were used for discovery and validation respectively. Pretreatment clinical factors associated with extrahepatic metastasis during follow‐up up to 5 years were identified using multivariate Cox regression model.Results: In early‐stage HCC (BCLC stage 0‐A), pretreatment platelet count (hazard ratio [HR], 1.04 per 10,000/μl; 95% CI, 1.01–1.07; P = 0.010) and serum alpha‐foetoprotein (AFP) >100 ng/ml (HR, 1.70; 95% CI, 1.04–2.78; P = 0.033) were the only two independent factors associated with extrahepatic metastasis. Receiver operating characteristic evidenced that pretreatment platelet count predicted metastasis better than AFP did. Survival tree analysis identified platelet counts P < 0.001) or >212,000/μl (HR, 2.12; 95% CI, 1.67–2.70; P < 0.001) to categorize patients into low and high risk of metastasis subgroups, which were verified using both validation cohorts.Conclusions: Pretreatment platelet count is a reliable marker to predict extrahepatic metastasis of early‐stage HCC following curative treatment. Cirrhotic thrombocytopenia contributes to relatively low metastasis incidence of HCC than many other cancers. High platelet count identifies a subgroup of HCC patients at high risk of metastasis, who might benefit from adjuvant therapies following initial curative treatment.Keywords
Funding Information
- Chang Gung Memorial Hospital (CMRPG3B1271-3;3C0261-3;3C0291-3; 391481-4)
- Ministry of Science and Technology (NSC100-2341-B-182-022-MY3)
- National Health Research Institute (NHRI-1X104-10408BI)
This publication has 29 references indexed in Scilit:
- Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trialsThe Lancet, 2012
- Paraneoplastic Thrombocytosis in Ovarian CancerNew England Journal of Medicine, 2012
- Direct Signaling between Platelets and Cancer Cells Induces an Epithelial-Mesenchymal-Like Transition and Promotes MetastasisCancer Cell, 2011
- Secreted ERBB3 Isoforms Are Serum Markers for Early Hepatoma in Patients with Chronic Hepatitis and CirrhosisJournal of Proteome Research, 2011
- Continuous Improvement of Survival Outcomes of Resection of Hepatocellular CarcinomaAnnals of Surgery, 2011
- Hepatocellular carcinoma with extrahepatic metastasisCancer, 2011
- Management of Hepatocellular Carcinoma: An Update ΔσHepatology, 2011
- Neuregulin/erythroblastic leukemia viral oncogene homolog 3 autocrine loop contributes to invasion and early recurrence of human hepatomaHepatology, 2010
- Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trialsThe Lancet, 2010
- Extrahepatic metastasis of hepatocellular carcinoma: incidence and risk factorsLiver International, 2008